|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis显示文摘 | Mouta Carreira C Nasser SM di Tomaso E et al | 2001 | Cancer Res2001，61，22： | 1 |
| 2 | Lymphatic metastasis inthe absence of functional intratumor lymphatics显示文摘 | Padera TP Ananth K Di Tomaso E | 2002 | Science2002，296，5574： | 1 |
| 3 | Direct evidence that bevacizumab,an anti-VEGF antibody,up-regulars SDF1 alpha,CXCR4,CXCL6,and neuropilin 1 in tumors from patients with rectal cancer显示文摘 | Xu L Duda DG di Tomaso E | 2009 | Cancer Res2009，69，20： | 1 |
| 4 | Lymphatic metastasis in the absence of functional intratumor lymphatics 显示文摘 | Padera TP Kadambi A Di Tomaso E | 2002 | Science2002，296，5574： | 1 |
| 5 | Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma 显示文摘 | Batchelor qF Duda DG di Tomaso E | 2010 | J Clin Oncol2010，28，： | 1 |
| 6 | Lym-phatic metastasis in the absence of functional intratumor lym-phatics显示文摘 | PADERA TP KADAMBI A DI TOMASO E | 2002 | Science2002，296，5574： | 1 |
| 7 | Tumour biology: herceptin acts as an antiangiagenic cocktail显示文摘 | Izumi Y Xu L di Tomaso E | 2002 | Nature2002，416，6878： | 1 |
| 8 | Direet evidence that bevaeizumab,an anti -VEGF antibody,up -regulates SDFlalpha,CXCR4,CXCL6,and neuropilin 1 in tumors from patients with rectal cancer 显示文摘 | Xu L Duda DG di Tomaso E | 2009 | Cancer Res2009，69，20： | 1 |
| 9 | Anti - vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions 显示文摘 | Lee CG Heijn M di Tomaso E et o2 | 2000 | Cancer Res2000，60，： | 1 |
| 10 | Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC) : Insights from a multidisciplinary phase Ⅱ study 显示文摘 | ZHU AX SAHANI DV DI TOMASO E | 2008 | J Clin Oncol2008，26，： | 1 |
| 11 | Glioblastoma recurrence after cediranib therapy in patients: lack of 'rebound' revascularization as mode of escape 显示文摘 | di Tomaso E Snuderl M Kamoun WS | 2011 | Cancer Res2011，71，1： | 1 |
| 12 | Lymphatic metastasis in the absence of functional intratumor lymhatics显示文摘 | PADERA T P KADAMBI A DI Tomaso E | 2002 | Science2002，296，5574： | 1 |
| 13 | PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment 显示文摘 | di Tomaso E London N Fuja D | 2009 | PLoS One2009，4，4： | 1 |
| 14 | Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy显示文摘 | Duda DG Cohen KS di Tomaso E | 2006 | J Clin Oncol2006，24，9： | 1 |
| 15 | Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions显示文摘 | Lee CG Heijn M di Tomaso E | 2000 | Cancer Res2000，60，： | 1 |
| 16 | Tumour biology:herceptin acts as an anti-angiogenic cocktail 显示文摘 | Izumi Y Xu L di Tomaso E | 2002 | Nature2002，416，： | 1 |
| 17 | Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer显示文摘 | Willett CG Boucher Y di Tomaso E | 2004 | Nat Med2004，10，2： | 1 |
| 18 | Direct evidence that the VEGF-specitlc antibody bevaeizumab has antivaseular effects in hu-nlan rectal cancer显示文摘 | Willett CG Boucher Y di Tomaso E | 2004 | Nat Med2004，10，2： | 1 |
| 19 | AZD2171,a pan-VEGF receptor tyrosine kinase inhibitor,normalizes tumor vasculature and alleviates edema in glioblastoma patients显示文摘 | Batchelor TT Sorensen AG di Tomaso E | 2007 | Cancer Cell2007，11，： | 1 |
| 20 | AZD2171, a pan VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients 显示文摘 | Batchelor T T Sorensen A G di Tomaso E | 2007 | Cancer Cell2007，11，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员